BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12672789)

  • 21. A phase II single institution single arm prospective study with paclitaxel, ifosfamide and cisplatin (TIP) as first-line chemotherapy in high-risk germ cell tumor patients with more than ten years follow-up and retrospective correlation with ERCC1, Topoisomerase 1, 2A, p53 and HER-2 expression.
    Ligia Cebotaru C; Zenovia Antone N; Diana Olteanu E; Bejinariu N; Buiga R; Todor N; Ioana Iancu D; Eliade Ciuleanu T; Nagy V
    J BUON; 2016; 21(3):698-708. PubMed ID: 27569093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience.
    Farhat F; Culine S; Théodore C; Békradda M; Terrier-Lacombe MJ; Droz JP
    Cancer; 1996 Mar; 77(6):1193-7. PubMed ID: 8635143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incorporation of TIP (paclitaxel, ifosfamide, cisplatin) into first-line therapy for intermediate to poor risk testicular germ cell tumors with unfavorable marker decline after initial two cycles chemotherapy: a report of three cases.
    Ishioka J; Kageyama Y; Ichiyanagi N; Fukuda H; Higashi Y
    Int J Urol; 2007 May; 14(5):455-7. PubMed ID: 17511735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of TIP (paclitaxel, ifosfamide and cisplatin) incorporated into induction chemotherapy for patients with intermediate- or poor-risk metastatic germ cell tumors.
    Nishikawa M; Miyake H; Muramaki M; Fujisawa M
    Med Oncol; 2014 Dec; 31(12):296. PubMed ID: 25341372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.
    Nishikawa M; Miyake H; Fujisawa M
    Int J Clin Oncol; 2016 Feb; 21(1):162-7. PubMed ID: 26123313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
    Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
    Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors.
    Bokemeyer C; Hartmann JT; Kuczyk MA; Truss MC; Beyer J; Jonas U; Kanz L
    World J Urol; 1996; 14(6):354-9. PubMed ID: 8986035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
    Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
    J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study.
    Lissoni AA; Colombo N; Pellegrino A; Parma G; Zola P; Katsaros D; Chiari S; Buda A; Landoni F; Peiretti M; Dell'anna T; Fruscio R; Signorelli M; Grassi R; Floriani I; Fossati R; Torri V; Rulli E
    Ann Oncol; 2009 Apr; 20(4):660-5. PubMed ID: 19181826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of recurrent metastatic testicular cancer, successfully treated with paclitaxel, ifomide and cisplatin].
    Yanada S; Ito H; Tomita M; Wada T; Hatano T; Kishimoto K; Egawa S
    Hinyokika Kiyo; 2008 Jan; 54(1):43-6. PubMed ID: 18260360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
    Kosmas C; Tsavaris NB; Polyzos A; Malamos NA; Katsikas M; Antonopoulos MJ
    Br J Cancer; 2000 Jan; 82(2):300-7. PubMed ID: 10646881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
    Farmakis D; Pectasides M; Pectasides D
    Eur Urol; 2005 Sep; 48(3):400-7. PubMed ID: 15964136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors.
    Motzer RJ; Cooper K; Geller NL; Bajorin DF; Dmitrovsky E; Herr H; Morse M; Fair W; Sogani P; Russo P
    Cancer; 1990 Dec; 66(12):2476-81. PubMed ID: 2174300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.
    Ghosn M; Droz JP; Theodore C; Pico JL; Baume D; Spielmann M; Ostronoff M; Moran A; Salloum E; Kramar A
    Cancer; 1988 Jul; 62(1):24-7. PubMed ID: 3133101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
    Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
    N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
    Bokemeyer C; Oechsle K; Honecker F; Mayer F; Hartmann JT; Waller CF; Böhlke I; Kollmannsberger C;
    Ann Oncol; 2008 Mar; 19(3):448-53. PubMed ID: 18006893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor.
    Rick O; Beyer J; Schwella N; Schubart H; Schleicher J; Siegert W
    Ann Oncol; 2001 Aug; 12(8):1151-5. PubMed ID: 11583199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
    Shinohara N; Harabayashi T; Suzuki S; Nagao K; Seki H; Murakumo M; Mitsuhashi K; Demura T; Nagamori S; Matsuyama H; Naito K; Nonomura K
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):402-7. PubMed ID: 16416335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma.
    Harstrick A; Schmoll HJ; Köhne-Wömpner CH; Bergmann L; Lammers U; Hohnloser J; Dölken G; Reichhardt P; Siegert W; Natt F
    Ann Oncol; 1991 Mar; 2(3):197-202. PubMed ID: 1710481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.